2020-10-23,Why BiondVax Pharmaceuticals Stock Imploded Today
2020-10-23,/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
2020-10-02,BiondVax Announces At-The-Market (ATM) Equity Offering Program
2020-08-31,BVXV: Phase 3 Data for Universal Flu Vaccine in Late September to Late October 2020
2020-08-20,BiondVax Announces Second Quarter 2020 Financial Results
2020-08-13,BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
2020-07-01,"Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial"
2020-06-30,BiondVax Announces First Quarter 2020 Financial Results
2020-06-16,BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81
2020-06-12,BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
2020-06-10,NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
2020-05-20,BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
2020-05-09,How BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Can Impact Your Portfolio Volatility
2020-05-04,BiondVax Announces Upcoming Expiration of Public Warrants
2020-03-24,New Directors Elected to BiondVax's Board of Directors
2020-03-19,BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
2020-02-05,Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
2020-01-16,BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
2019-12-04,BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled
2019-11-26,BiondVax Announces Third Quarter 2019 Financial Results and Business Update
2019-11-18,"Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial"
2019-11-11,Do Directors Own BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Shares?
2019-10-07,BiondVax Receives 4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
2019-08-28,BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
2019-08-01,BVXV: Raises $20 Million; Phase 3 Trial Fully Funded
2019-07-16,BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
2019-07-08,"First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial"
2019-06-26,European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to 24million
2019-06-25,BiondVax Gets OK to Build Plant in Israel (BVXV)
2019-06-18,Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
2019-06-12,BVXV: Rights Offering to Finance Company Through Phase 3 Trial Results
2019-06-10,"BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process"
2019-05-30,BiondVax Announces First Quarter 2019 Financial Results
2019-05-13,BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
2019-04-30,BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
2019-04-22,European Investment Bank (EIB) Extends Financing Agreement to 24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
2019-04-17,BVXV: Update on Phase 3 Clinical Trial of Universal Influenza Vaccine
2019-04-15,BiondVax Universal Flu Vaccine Patent Application Accepted in Australia
2019-03-28,BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
2019-03-21,Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate
2018-11-28,"Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals  Research Highlights Growth, Revenue, and Consolidated Results"
2018-11-26,BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
2018-11-20,BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine
2018-11-19,BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
2018-11-13,BiondVax Announces Third Quarter 2018 Financial Results
2018-10-24,"BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants"
2018-10-22,BiondVax Receives 8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
2018-10-17,"Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals  New Horizons, Emerging Trends, and Upcoming Developments"
2018-09-05,BVXV: Phase 3 Trial of M-001 Underway
2018-09-04,BiondVax to Present at Influenza 2018 Oxford Conference
2018-08-22,BiondVax Announces Second Quarter 2018 Financial Results
2018-08-20,"Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software  New Horizons, Emerging Trends, and Upcoming Developments"
2018-08-20,BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
2018-08-14,BiondVax Receives Second 6M Tranche Disbursement From the European Investment Bank (EIB)
2018-08-08,First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
2018-06-28,Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
2018-06-19,BiondVax Receives Its First 6M Tranche Disbursement From the European Investment Bank (EIB)
2018-06-05,"Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals  New Research Emphasizes Economic Growth"
2018-06-01,BVXV: Increased Media Coverage for M-001 Ahead of Phase 3 Clinical Trial
2018-05-29,BiondVax Announces First Quarter 2018 Financial Results
2018-05-07,BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18
2018-04-30,BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
2018-04-13,Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US
2018-04-12,BiondVax to Present at Universal Influenza Vaccines Conference
2018-04-11,BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States
2018-04-09,"Recent Analysis Shows Norbord, BiondVax Pharmaceuticals, NXP Semiconductors N.V, Lazard, Canadian Solar, and Sierra Wireless Market Influences  Renewed Outlook, Key Drivers of Growth"
2018-03-15,"Recent Analysis Shows KB Financial Group, Southern Missouri, Net 1 UEPS Technologies, Financial Engines, Carbonite, and BiondVax Pharmaceuticals Market Influences  Renewed Outlook, Key Drivers of Growth"
2018-03-13,BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
2018-02-08,BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
2018-01-02,BiondVax Universal Flu Vaccine Patent Granted in India
2017-12-27,BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)
2017-12-12,BVXV: Planning Continues for M-001 Phase 3 Program 
2017-12-11,Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders
2017-12-05,BiondVax's CEO Issues Letter to Shareholders
2017-11-28,BiondVax Provides Third Quarter 2017 Financial Results and Update
2017-11-20,BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine
2017-09-20,BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine
2017-09-18,BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option
2017-09-13,BiondVax Announces Pricing of Public Offering of American Depositary Shares
2017-09-13,BiondVax Announces Public Offering of American Depositary Shares
2017-09-13,Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?
2017-09-12,Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates
2017-08-31,Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
2017-08-31,BiondVax Provides Second Quarter 2017 Financial Results and Update
2017-08-14,BiondVax Receives Additional Grant Funding
2017-08-01,BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine
2017-07-20,BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine
2017-07-18,BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
2017-07-06,BVXV: Secures $22 Million Loan Agreement with European Investment Bank
2017-06-28,BiondVax's CEO Provides First Half 2017 General Corporate Update
2017-06-19,European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative
2017-06-12,Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials
2017-06-02,BVXV: Immunogenicity Results From Phase 2b Trial of M-001 Expected Soon
2017-05-30,BiondVax Announces First Quarter 2017 Financial Results and Update
2017-05-08,BVXV: Awarded Grant to Build Commercial Scale Facility for Production of M-001
2017-04-28,BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update
2017-03-30,BiondVax Gets Approval to Build Plant in Israel
2017-03-30,BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
2017-03-13,BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal
2017-01-20,BVXV: New Publication Shows M-001 Incites Immune Protection Against Current and Future Influenza Strains
